Comparative efficacy and potency of long-term therapy with glipizide or glyburide in patients with type 2 diabetes mellitus

American Journal of the Medical Sciences

Volumn 319, Issue 3, 2000, Pages 143-148

  Kitabchi, Abbas E ^a   Kaminska, Elizabeth ^a   Fisher, Joseph N ^a   Sherman, Amy ^a   Pitts, Kathy ^a   Bush, Andrew ^a   Bryer Ash, Michael ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Equipotency; Glipizide; Glyburide; Postprandial glucose; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIPIZIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DRUG EFFICACY; DRUG POTENCY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESPONSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; SINGLE BLIND PROCEDURE;

EID: 0034119920     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200003000-00003     Document Type: Article

References (27)

1. Seltzer HS, Allen EW, Herron AL Jr, et al. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 1967;46:323-35.
2. Kosaka K, Hagura R, Kuzuya T. Insulin response in equivocal and definite diabetes, with special reference to subjects who had mild glucose intolerance but later developed definite diabetes. Diabetes 1977;26:944-52.
3. Lebovitz HE. Oral antidiabetic agents. In: Kahn CR, Weir GC, editors. Joslin's diabetes mellitus. Philadelphia: Lea & Febiger; 1994. p. 508-29.
4. Luft R, Wajngot A, Efendic S. On the pathogenesis of maturity-onset diabetes. Diabetes Care 1981;4:58-63.
5. Smith DE, Wing RR. Diminished weight loss and behavioral compliance during repeated diets in obese patients with type II diabetes. Health Psychol 1991;10:378-83.
6. Pascale RW, Wing RR, Blair EH, et al. The effect of weight loss on change in waist-to-hip ratio in patients with type II diabetes. Int J Obes Relat Metab Disord. 1992;16:59-65.
7. Diagnosis and Treatment. In: The physicians' guide to type II diabetes (NIDDM). New York: American Diabetes Association Press; 1984.
8. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes 1979;28:1039-57.
9. Kitabchi AE, Bryer-Ash M. NIDDM: New aspects of management. Hosp Prac 1997;32:135-64.
10. Rosenstock J, Samels E, Muchmore D, et al. Glimepiride, a new once-daily sulfonylurea. Diabetes Care 1996; 19:1194-9.
11. Duckworth WC, Solomon SS, Kitabchi AE. Effect of chronic sulfonylurea therapy on plasma insulin and proinsulin levels. J Clin Endocrinol Metab. 1972;35:585-91.
12. Lev JD, Zeidler A, Kumar D. Glyburide and glipizide in treatment of diabetic patients with secondary failures to tolazamide or chlorpropamide. Diabetes Care 1987;10:679-82.
13. Ponte CD. The clinical use of oral sulfonylureas in the management of non-insulin-dependent diabetes mellitus (NIDDM). WV Med J 1990; 86:455-8.
14. Berelowitz M, Fischette C, Cefalu W, et al. Comparative efficacy of a once-daily controlled release formulation of glipizide and immediate release glipizide in patients with NIDDM. Diabetes Care 1994;17:1460-4.
15. Groop L, Groop PH, Stenman S, et al. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care 1987;10:71-8.
16. Birkeland KI, Furuseth K, Melander A. Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Diabetes Care 1994;17:45-54.
17. Physicians' Desk Reference, 50th ed. Montvale (NJ): Medical Economics Publications; 1996. p. 2623-5.
18. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care 1994;17:519-22.
19. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual β-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. J Clin Endocrinol Metab. 1987; 65:30-36.
20. Soeldner J, Fajans SS, Sussman KE, editors. The intravenous glucose tolerance test. In: Diabetes mellitus: diagnosis and treatment. New York: American Diabetes Association Press; 1971. p. 107-33.
21. Schneider SH, Amorosa LF, Khachadurian AK, et al. Studies on the mechanism of improved glucose control during regular exercise in Type 2 (non-insulin-dependent) diabetes. Diabetologia 1984;26:355-60.
22. Bogardus C, Rasmussin E, Robbins DC, et al. Effect of physical training and diet therapy on carbohydrate metabolism in patients with glucose intolerance and non-insulin-dependent diabetes mellitus. Diabetes 1984;33:311-8.
23. Shorr RI, Ray WA, Daugherty JR, et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996;44:751-5.
24. Groop L, Wahlin-Boll E, Groop PH, et al. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetes. Eur J Clin Pharmacol 1985;28:697-704.
25. Groop L, Luzi L, Melander A, et al. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes. 1985;36:1320-8.
26. Sami T, Kabadi UM, Moshiri S. The effect on metabolic control of second-generation sulfonylurea drugs in patients with NIDDM after secondary failure to first-generation agents. J Fam Pract 1996;43:370-4.
27. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997;5:177-269.